Potential Predictors of Response to CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Data.
Carmen Sánchez-RodríguezAna Beatriz Gago-VeigaDavid Garcia AzorinÁngel Luis Guerrero-PeralAlicia Gonzalez-MartinezPublished in: Current pain and headache reports (2023)
Migraine features such as unilateral pain and positive triptan response and chronic features such as daily headache or medication overuse (MO) emerge as predictors of positive outcomes, potentially linked to elevated baseline serum anti-calcitonin gene-related peptide (anti-CGRP) levels. Demographic and baseline characteristics, encompassing obesity, psychiatric comorbidities, and prior refractoriness to prophylactic treatments, are associated with poor responses in both treatment-naïve patients and after-switch scenarios. Nevertheless, the consistency of these predictors across diverse populations requires further investigation. Recent RWD literature highlights emerging predictors of response of different sources among patients with CM receiving anti-CGRP therapies. Comprehending these predictors and identifying novel biomarkers of response hold the potential to refine treatment strategies for CM patients, enhancing their management and therapeutic outcomes.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- metabolic syndrome
- peritoneal dialysis
- healthcare
- physical activity
- mental health
- skeletal muscle
- machine learning
- adipose tissue
- body mass index
- pain management
- weight loss
- electronic health record
- transcription factor
- patient reported
- combination therapy
- data analysis
- glycemic control